Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

GTX-RT in Borderline Resectable Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Capecitabine
Drug: Gemcitabine
Drug: Docetaxel
Radiation: Stereotactic body radiation therapy (SBRT)
Other: Restaging review after radiation
Procedure: Surgery
Drug: 5-Fluorouracil

First Posted Date: 2012-12-21

Last Posted Date: 2015-08-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 9

Registration Number: NCT01754623

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Ziv-aflibercept

First Posted Date: 2012-12-11

Last Posted Date: 2020-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT01747551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Phase 1

Completed

Conditions: Stage IIB Rectal Cancer
Recurrent Rectal Cancer
Stage IIIC Rectal Cancer
Stage IIA Rectal Cancer
Stage IIC Rectal Cancer
Stage IIIA Rectal Cancer
Stage IIIB Rectal Cancer

Interventions: Drug: trametinib
Drug: fluorouracil
Radiation: radiation therapy

First Posted Date: 2012-12-04

Last Posted Date: 2023-09-18

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT01740648

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

and more 1 locations

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Phase 2

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Erlotinib
Drug: Folinic Acid
Drug: Irinotecan
Drug: 5-FU

First Posted Date: 2012-11-20

Last Posted Date: 2017-07-19

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 150

Registration Number: NCT01729481

Locations: 🇩🇪
University of Munich, Munich, Germany

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Phase 3

Completed

Conditions: Adenocarcinoma of the Oesophagus
Oesophageal Tumours
Junctional Tumours
Adenocarcinoma of the Oesophago-gastric Junction
Oesophageal Cancer

Interventions: Radiation: (41.4 Gy/23 fractions)
Drug: Epirubicin
Drug: Cisplatin / Oxaliplatin
Drug: Paclitaxel
Drug: 5 Flourouracil/ Capecitabine
Drug: Carboplatin
Drug: Docetaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2012-11-15

Last Posted Date: 2022-09-30

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 377

Registration Number: NCT01726452

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp, Cambridge, United Kingdom
🇸🇪
Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
🇬🇧
Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, United Kingdom

and more 26 locations

Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: levo-folinic acid
Drug: 5-fluorouracil
Drug: Capecitabine

First Posted Date: 2012-10-31

Last Posted Date: 2023-04-12

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 230

Registration Number: NCT01718873

Locations: 🇮🇹
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy

Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer

Phase 1

Conditions: Rectal Cancer

Interventions: Radiation: Radiotherapy
Procedure: Hyperthermia
Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2012-10-30

Last Posted Date: 2017-08-11

Lead Sponsor: University of Erlangen-Nürnberg Medical School

Target Recruit Count: 59

Registration Number: NCT01716949

Locations: 🇩🇪
LMU München, Campus Großhadern, Medizinische Klinik III, Hyperthermie, München, Germany
🇩🇪
Klinik Bad Trissl, Innere Medizin, Bad Trissl, Germany
🇩🇪
Schlossbergklinik, Oberstaufen, Germany

and more 3 locations

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

Phase 2

Completed

Conditions: Gastroesophageal Cancer
Gastric Cancer
Metastatic Esophageal Cancer

Interventions: Drug: Docetaxel
Drug: Leucovorin
Drug: Fluorouracil
Drug: Cisplatin

First Posted Date: 2012-10-26

Last Posted Date: 2019-03-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT01715233

Locations: 🇺🇸
SKCCC at Johns Hopkins, Baltimore, Maryland, United States

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Stage IVA Oropharyngeal Carcinoma AJCC v7
Stage IVB Oropharyngeal Carcinoma AJCC v7
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Fluorouracil
Drug: Hydroxyurea
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Placebo Administration
Radiation: Radiation Therapy
Drug: Veliparib

First Posted Date: 2012-10-22

Last Posted Date: 2023-06-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT01711541

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 2 locations

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Xeloda
Drug: Calcium folinate (CF)
Drug: 5-FU
Drug: Bevacizumab

First Posted Date: 2012-09-06

Last Posted Date: 2012-09-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT01679327

Locations: 🇨🇳
Cancer Institute&Hospital Chinese Academy of Medical Sciences, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy